US 12,465,249 B2
Methods and systems for endobronchial diagnostics
Surag Mantri, Sunnyvale, CA (US); and Srikanth Radhakrishnan, Cupertino, CA (US)
Assigned to Pulmonx Corporation, Redwood City, CA (US)
Filed by Pulmonx Corporation, Redwood City, CA (US)
Filed on Oct. 17, 2023, as Appl. No. 18/488,411.
Application 16/107,849 is a division of application No. 14/339,197, filed on Jul. 23, 2014, granted, now 10,076,271, issued on Sep. 18, 2018.
Application 14/339,197 is a division of application No. 13/174,633, filed on Jun. 30, 2011, granted, now 8,808,194, issued on Aug. 19, 2014.
Application 18/488,411 is a continuation of application No. 17/163,173, filed on Jan. 29, 2021, granted, now 11,819,328.
Application 17/163,173 is a continuation of application No. 16/107,849, filed on Aug. 21, 2018, granted, now 10,932,706, issued on Mar. 2, 2021.
Claims priority of provisional application 61/360,811, filed on Jul. 1, 2010.
Prior Publication US 2024/0041362 A1, Feb. 8, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61B 5/1455 (2006.01); A61B 1/00 (2006.01); A61B 1/267 (2006.01); A61B 5/00 (2006.01); A61B 5/08 (2006.01); A61B 5/085 (2006.01); A61B 5/087 (2006.01); A61B 5/091 (2006.01); A61B 5/145 (2006.01); A61M 16/00 (2006.01); A61M 16/04 (2006.01); A61M 16/10 (2006.01)
CPC A61B 5/14552 (2013.01) [A61B 1/00082 (2013.01); A61B 1/2676 (2013.01); A61B 5/08 (2013.01); A61B 5/085 (2013.01); A61B 5/087 (2013.01); A61B 5/091 (2013.01); A61B 5/14542 (2013.01); A61B 5/6853 (2013.01); A61M 16/0003 (2014.02); A61M 16/0404 (2014.02); A61M 2016/0036 (2013.01); A61M 2016/102 (2013.01); A61M 2230/205 (2013.01); A61M 2230/43 (2013.01)] 16 Claims
OG exemplary drawing
 
1. A method of assessing the functionality of a lung segment of a patient, the method comprising:
introducing a diagnostic catheter into the lung segment, wherein the diagnostic catheter comprises a distal end comprising an occluding member and a proximal end configured to be coupled to a console;
determining an average tidal flow volume in the lung segment, wherein the average tidal flow volume is determined by calculating an average tidal expiratory volume during a given number of cycles;
determining total lung capacity of the patient; and
determining a treatment option based on the average tidal expiratory volume over the total lung capacity.